Ontology highlight
ABSTRACT:
SUBMITTER: Callahan MK
PROVIDER: S-EPMC3653249 | biostudies-literature | 2013 Mar-Apr
REPOSITORIES: biostudies-literature
Callahan Margaret K MK Postow Michael A MA Wolchok Jedd D JD
Clinics in dermatology 20130301 2
In 2011, the U.S. Food and Drug Administration approved the first new therapy for melanoma in more than a decade, ipilimumab (Yervoy). Ipilimumab is a novel antibody that blocks cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), a regulatory molecule expressed on activated T cells. Blockade of this important immune checkpoint can lead to durable tumor regression, and phase III studies show an overall survival benefit for patients with advanced melanoma. During the clinical development of ipil ...[more]